105 related articles for article (PubMed ID: 11366020)
1. Soaring prices, soaring sales.
Grinberg L
GMHC Treat Issues; 1998 Dec; 12(12):5-7. PubMed ID: 11366020
[TBL] [Abstract][Full Text] [Related]
2. New drug pricing: progress on World AIDS Day?
James JS
AIDS Treat News; 1998 Dec; (No 308):8. PubMed ID: 11366077
[TBL] [Abstract][Full Text] [Related]
3. Advocates call for fair drug pricing.
Highleyman L
BETA; 1998 Oct; ():3. PubMed ID: 11365988
[TBL] [Abstract][Full Text] [Related]
4. New drug pricing consensus letter, sign-ons requested.
AIDS Treat News; 1998 Sep; (302):4. PubMed ID: 11365762
[TBL] [Abstract][Full Text] [Related]
5. Access to efavirenz and amprenavir.
Gilden D
GMHC Treat Issues; 1998 Oct; 12(10):12. PubMed ID: 11365902
[TBL] [Abstract][Full Text] [Related]
6. The high cost of fighting HIV.
Body Posit; 1998 Dec; 11(12):15. PubMed ID: 11366135
[TBL] [Abstract][Full Text] [Related]
7. Sparing the protease for some spoils the price for all.
Grinberg L
GMHC Treat Issues; 1998 Sep; 12(9):1-2. PubMed ID: 11365802
[TBL] [Abstract][Full Text] [Related]
8. Glaxo Wellcome announces abacavir pricing.
Newsline People AIDS Coalit N Y; 1999 Jan; ():35. PubMed ID: 11367192
[TBL] [Abstract][Full Text] [Related]
9. Opportunistic pricing: a new scourge, a new call for action.
Proj Inf Perspect; 1998 Dec; (26):1-5. PubMed ID: 11366486
[TBL] [Abstract][Full Text] [Related]
10. New drug approved.
AIDS Policy Law; 1998 Oct; 13(18):12. PubMed ID: 11365934
[TBL] [Abstract][Full Text] [Related]
11. FDA approves efavirenz. Food and Drug Administration.
Highleyman L
BETA; 1998 Oct; ():3. PubMed ID: 11365987
[TBL] [Abstract][Full Text] [Related]
12. Another expensive drug for your cocktail.
Gilden D
GMHC Treat Issues; 1998 Sep; 12(9):3-6. PubMed ID: 11365806
[TBL] [Abstract][Full Text] [Related]
13. [FDA approval of the first HIV anti-retroviral from DuPont-Pharma: SUSTIVA (efavirenz). SUSTIVA should be associated with other anti-retrovirals and could be considered a new alternative first line treatment].
Allerg Immunol (Paris); 1998 Oct; 30(8):268-70. PubMed ID: 9846197
[No Abstract] [Full Text] [Related]
14. Drug prices.
AIDS Policy Law; 1996 Dec; 11(22):12. PubMed ID: 11364060
[TBL] [Abstract][Full Text] [Related]
15. Efavirenz's complications.
GMHC Treat Issues; 1998 May; 12(5):6. PubMed ID: 11365477
[TBL] [Abstract][Full Text] [Related]
16. Ribavirin approved with a big fat price.
Falkenberg J
Notes Undergr; 1998; (No 37):10-1. PubMed ID: 11365818
[TBL] [Abstract][Full Text] [Related]
17. Four-drug regimens may be better.
AIDS Patient Care STDS; 2000 Dec; 14(12):671. PubMed ID: 11119435
[No Abstract] [Full Text] [Related]
18. Now approved: Sustiva in combination offers patients a new first-line therapy.
Fac Notes (New Orleans La); 1998; 10(6):10. PubMed ID: 11366140
[TBL] [Abstract][Full Text] [Related]
19. Dupont data supports earlier findings.
Slovick J
Posit Living; 1999 Nov; 8(10):45. PubMed ID: 11367331
[TBL] [Abstract][Full Text] [Related]
20. Efavirenz (Sustiva) receives FDA approval. Food and Drug Administration.
Proj Inf Perspect; 1998 Dec; (26):11. PubMed ID: 11366487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
